Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 3 7Phase 1/2 1

Status

Terminated 6Withdrawn 1

Sponsor Class

INDUSTRY 7

Study Type

Interventional 7

Sponsor

Cancer Type

Classical hematology 2

Conditions

Leiomyoma 7Anemia 2

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 362Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 3 × telapristone acetate × Clear all
NCT00702702 2014-08-21

Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids

Repros Therapeutics Inc.

Phase 3 Terminated
56 enrolled 1 chart
Classical hematology

Anemia, Leiomyoma

NCT00735553 2014-08-21

Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids

Repros Therapeutics Inc.

Phase 3 Terminated
77 enrolled 1 chart

Leiomyoma

NCT00737282 2014-08-21

Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids

Repros Therapeutics Inc.

Phase 3 Terminated
175 enrolled 1 chart

Leiomyoma

NCT00785356 2014-08-21

Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids

Repros Therapeutics Inc.

Phase 3 Terminated
8 enrolled 1 chart
Classical hematology

Anemia, Leiomyoma

NCT00853567 2014-08-21

Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids

Repros Therapeutics Inc.

Phase 3 Terminated
71 enrolled 1 chart

Leiomyoma

NCT01069120 2014-08-21

Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids

Repros Therapeutics Inc.

Phase 3 Terminated
27 enrolled 1 chart

Leiomyoma

NCT00874302 2014-06-27

Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms

Repros Therapeutics Inc.

Phase 3 Withdrawn

Leiomyoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡